FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3192950604> ?p ?o ?g. }

• W3192950604 abstract "Summary Background We have assessed the safety and immunogenicity of the COVID-19 vaccine MVC-COV1901, a recombinant protein vaccine containing prefusion-stabilized spike protein S-2P adjuvanted with CpG 1018 and aluminium hydroxide. Methods This is a phase 2, prospective, randomised, double-blind, placebo-controlled, and multi-centre study to evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 vaccine candidate MVC-COV1901. The study comprised 3,844 participants of ≥ 20 years who were generally healthy or with stable pre-existing medical conditions. The study participants were randomly assigned in a 6:1 ratio to receive either MVC-COV1901 containing 15 μg of S-2P protein or placebo containing saline. Participants received two doses of MVC-COV1901 or placebo, administered 28 days apart via intramuscular injection. The primary outcomes were to evaluate the safety, tolerability, and immunogenicity of MVC-COV1901 from Day 1 (the day of first vaccination) to Day 57 (28 days after the second dose). Immunogenicity of MVC-COV1901 was assessed through geometric mean titres (GMT) and seroconversion rates (SCR) of neutralising antibody and antigen-specific immunoglobulin. This clinical trial is registered at ClinicalTrials.gov: NCT04695652. Findings From the start of this phase 2 trial to the time of interim analysis, no vaccine-related Serious Adverse Events (SAEs) were recorded. The most common solicited adverse events across all study participants were pain at the injection site (64%), and malaise/fatigue (35%). Fever was rarely reported ( Interpretation MVC-COV1901 shows good safety profiles and promising immunogenicity responses. The current data supports MVC-COV1901 to enter phase 3 efficacy trials and could enable regulatory considerations for Emergency Use Authorisation (EUA). Funding Medigen Vaccine Biologics Corporation and Taiwan Centres for Disease Control." @default.
• W3192950604 created "2021-08-16" @default.
• W3192950604 creator A5000365066 @default.
• W3192950604 creator A5002189335 @default.
• W3192950604 creator A5031585842 @default.
• W3192950604 creator A5034441934 @default.
• W3192950604 creator A5035955045 @default.
• W3192950604 creator A5038207357 @default.
• W3192950604 creator A5040417524 @default.
• W3192950604 creator A5044246659 @default.
• W3192950604 creator A5045652727 @default.
• W3192950604 creator A5047676512 @default.
• W3192950604 creator A5061079959 @default.
• W3192950604 creator A5061944444 @default.
• W3192950604 creator A5071015273 @default.
• W3192950604 creator A5073962059 @default.
• W3192950604 creator A5077274925 @default.
• W3192950604 creator A5077457507 @default.
• W3192950604 creator A5081240292 @default.
• W3192950604 creator A5088202717 @default.
• W3192950604 creator A5090574808 @default.
• W3192950604 creator A5091728005 @default.
• W3192950604 date "2021-08-08" @default.
• W3192950604 modified "2023-10-18" @default.
• W3192950604 title "Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blinded, Randomised, Placebo-Controlled Phase 2 Trial" @default.
• W3192950604 cites W3004280078 @default.
• W3192950604 cites W3007643904 @default.
• W3192950604 cites W3023609288 @default.
• W3192950604 cites W3041985244 @default.
• W3192950604 cites W3042833857 @default.
• W3192950604 cites W3048620154 @default.
• W3192950604 cites W3086755607 @default.
• W3192950604 cites W3105914759 @default.
• W3192950604 cites W3124177967 @default.
• W3192950604 cites W3128853581 @default.
• W3192950604 cites W3152845777 @default.
• W3192950604 cites W3163785571 @default.
• W3192950604 cites W3175530995 @default.
• W3192950604 cites W3178771308 @default.
• W3192950604 cites W3203490635 @default.
• W3192950604 doi "https://doi.org/10.34944/dspace/6966" @default.
• W3192950604 hasPublicationYear "2021" @default.
• W3192950604 type Work @default.
• W3192950604 sameAs 3192950604 @default.
• W3192950604 citedByCount "0" @default.
• W3192950604 crossrefType "posted-content" @default.
• W3192950604 hasAuthorship W3192950604A5000365066 @default.
• W3192950604 hasAuthorship W3192950604A5002189335 @default.
• W3192950604 hasAuthorship W3192950604A5031585842 @default.
• W3192950604 hasAuthorship W3192950604A5034441934 @default.
• W3192950604 hasAuthorship W3192950604A5035955045 @default.
• W3192950604 hasAuthorship W3192950604A5038207357 @default.
• W3192950604 hasAuthorship W3192950604A5040417524 @default.
• W3192950604 hasAuthorship W3192950604A5044246659 @default.
• W3192950604 hasAuthorship W3192950604A5045652727 @default.
• W3192950604 hasAuthorship W3192950604A5047676512 @default.
• W3192950604 hasAuthorship W3192950604A5061079959 @default.
• W3192950604 hasAuthorship W3192950604A5061944444 @default.
• W3192950604 hasAuthorship W3192950604A5071015273 @default.
• W3192950604 hasAuthorship W3192950604A5073962059 @default.
• W3192950604 hasAuthorship W3192950604A5077274925 @default.
• W3192950604 hasAuthorship W3192950604A5077457507 @default.
• W3192950604 hasAuthorship W3192950604A5081240292 @default.
• W3192950604 hasAuthorship W3192950604A5088202717 @default.
• W3192950604 hasAuthorship W3192950604A5090574808 @default.
• W3192950604 hasAuthorship W3192950604A5091728005 @default.
• W3192950604 hasConcept C126322002 @default.
• W3192950604 hasConcept C142724271 @default.
• W3192950604 hasConcept C159654299 @default.
• W3192950604 hasConcept C197934379 @default.
• W3192950604 hasConcept C203014093 @default.
• W3192950604 hasConcept C204787440 @default.
• W3192950604 hasConcept C27081682 @default.
• W3192950604 hasConcept C2777451964 @default.
• W3192950604 hasConcept C2778375690 @default.
• W3192950604 hasConcept C2780868878 @default.
• W3192950604 hasConcept C535046627 @default.
• W3192950604 hasConcept C61943457 @default.
• W3192950604 hasConcept C71924100 @default.
• W3192950604 hasConceptScore W3192950604C126322002 @default.
• W3192950604 hasConceptScore W3192950604C142724271 @default.
• W3192950604 hasConceptScore W3192950604C159654299 @default.
• W3192950604 hasConceptScore W3192950604C197934379 @default.
• W3192950604 hasConceptScore W3192950604C203014093 @default.
• W3192950604 hasConceptScore W3192950604C204787440 @default.
• W3192950604 hasConceptScore W3192950604C27081682 @default.
• W3192950604 hasConceptScore W3192950604C2777451964 @default.
• W3192950604 hasConceptScore W3192950604C2778375690 @default.
• W3192950604 hasConceptScore W3192950604C2780868878 @default.
• W3192950604 hasConceptScore W3192950604C535046627 @default.
• W3192950604 hasConceptScore W3192950604C61943457 @default.
• W3192950604 hasConceptScore W3192950604C71924100 @default.
• W3192950604 hasLocation W31929506041 @default.
• W3192950604 hasOpenAccess W3192950604 @default.
• W3192950604 hasPrimaryLocation W31929506041 @default.
• W3192950604 hasRelatedWork W3042383115 @default.
• W3192950604 hasRelatedWork W3088965854 @default.
• W3192950604 hasRelatedWork W3092607529 @default.
• W3192950604 hasRelatedWork W3113446844 @default.
• W3192950604 hasRelatedWork W3123606124 @default.

• next